Dr. Wataru Akahata
Kyoto University
For the development of a Covid – 19 vaccine specificially targeted to the receptor-binding domain of the viral S protein using expertise gained during successful development of anti-malaria and anti-chikungunya vaccines.
For a collaborative effort with the Lingwood and Schmidt labs combining vaccine immunology and nanotechnology expertise to rapidly test and characterize COVID – 19 vaccine candidates in high-throughput.
Dr. Jeff Biernaskie
University of Calgary
To study the immune basis of COVID – 19 related acute respiratory distress syndrome (ARDs) via longitudinal study of patients undergoing placebo and convalescent plasma treatment in order to inform evidence-based repurposing of targeted immunotherapies to improve outcomes for critically-ill patients affected by COVID – 19.
Dr. Jim Boonyaratanakornkit
Fred Hutchinson Cancer Research Center
To probe the human B cell repertoire for SARS-CoV-2-protective B cells from pre -immune individuals in order to guide vaccine and monoclonal antibody design against COVID – .
Dr. J. Brian Byrd
University of Michigan Medical School
To support a randomized, controlled clinical trial testing whether continuation, or discontinuation of two common types of blood pressure medication leads to better outcomes in patients hospitalized with COVID – 19.
Dr. Brandon J. DeKosky
The University of Kansas
For high-throughput screening of antibody responses in COVID – 19 patients for therapeutic discovery and to accelerate vaccine design.
Dr. John Eikelboom
McMaster University
For the ACT program design using innovative and adaptive methodology to find a safe, effective treatment to slow the progression of COVID – 2019 across 80 sites in 8 countries over 6 months.
Dr. Steven Marc Friedman
University Health Network, University of Toronto
For a comparative study to validate saliva as a test for SARS-CoV-2 , as an alternative to nasopharyngeal swab testing and its associated problems, including depletion of swabs and personal protective equipment, and risk of nosocomial infection from close proximity of health care worker and patient being tested
Dr. Judith Frydman
Stanford University
For using their combined expertise in virology and in multisubunit protein production to engineer virus-like particles (VLPs), which will allow for rapid testing of the neutralization capacity of recovered patient sera (in collaboration with the Blish lab) or designed antibodies targeting the S protein (in collaboration with the Wells lab).
Dr. Patrick Giguère
University of Ottawa
For the discovery of CoV-2 particle entry in absence of ACE2 and genome-wide gain-of- function screening to identify new secondary receptors / co-receptors / auxiliary proteins that facilitate viral entry / fusion.
Dr. Douglas Goetz
Ohio University
To determine the potential of GSK-3 inhibitors to diminish the cytokine storm associated with COVID – 19.
Dr. Ewan Goligher
University Health Network and University of Manitoba
To support the Antithrombotic Therapy to Ameliorate Complications of COVID – (ATTACC) trial. This international, multicenter, adaptive, open-label randomized clinical trial will examine the impact of therapeutic anticoagulation in comparison to standard venous thromboprophylaxis on the risk of intubation and death in hospitalized patients with COVID – 19.
Dr. Shirley Hsin-Ju Mei
Ottawa Hospital Research Institute
For the TURQUOISE Ottawa COVID – 19 study profiling immune responses of COVID – 19 patients admitted to the intensive care unit (ICU), with a focus on the potential immunomodulatory function of mesenchymal stem cells.
Dr. Eva Harris
UC Berkeley
To perform a randomized, representative, community-based, longitudinal study of short and long-term spread, asymptomatic infection rates, disease risk modifying factors and effects of non-pharmacological interventions for COVID – 823 in the Bay Area.
Dr. Patrick Hsu
UC Berkeley
For the discovery of diagnostic and actionable biomarkers of COVID – 19.
Dr. Akiko Iwasaki
Yale University
To elucidate the single cell transcriptional profiles of infected tissues from COVID – 19 patients.
Dr. Peter K. Jackson
Stanford University School of Medicine
For elucidating a newly discovered mechanism by which the SARS-CoV-2 virus binds to its receptor (s) on trachea and nasal epithelium and defining a new drug target to block viral uptake and spread.
Dr. Naftali Kaminski
Yale University
To perform a clinical trial assessing the efficacy of sobetirome in reducing the requirements for mechanical ventilation and mortality of moderate to severe hospitalized COVID – 823 patients.
Dr. Ronald Levy
Stanford University
To generate a vaccine against SARS-CoV-2 using a novel polymer for mRNA protection.
To explore the pathogenic role of neutrophil extracellular traps (NETs) in COVID – 823 by testing a strategy to dismantle NETs using a novel therapeutic to ameliorate acute lung injury.
Dr. Rajeev Malhotra
Massachusetts General Hospital
To identify novel risk factors that determine which COVID – 19 patients are at the highest risk (eg, those needing ICU care or to be on a ventilator) or who develop cardiac injury, with a particular focus on baseline vascular abnormalities.
Dr. Amanda J. Martinot
Tufts University Cummings School of Veterinary Medicine
For comparison of pre-clinical animal models for vaccine and therapeutic development and the basic immunology and virulence determinants underlying host-pathogen interactions.
Dr. Roman Melnyk
University of Toronto and The Hospital for Sick Children
For high-throughput screening of repurposed FDA-approved drugs for their efficacy to prevent SARS-CoV2 entry by modifying endosomal pH and testing in preclinical hamster and ferret models of Covid – 19 in collaboration with the Kozak and Falzarano labs.
Dr. Anders Näär
UC Berkeley
To develop anti-viral COVID – 19 therapeutics based on direct targeting of the viral RNA genome using LNA anti-sense oligonucleotides.
Dr. Mihai Netea
Radboud University Medical Center
To support a randomized clinical trial to investigate whether vaccination with BCG is able to decrease the incidence and severity of COVID – 19 infection in elderly individuals.
Dr. Elizabeth L. Ogburn
Johns Hopkins School of Public Health
For developing the COVID Collaboration Platform to bring disparate research teams working on the same clinical research questions together to share protocols, data, and evidence. Outside of a few centrally organized trials, most COVID – 19 randomized clinical trials are small and / or redundant — and it’s only by aggregating evidence across these trials that we will learn how to best treat COVID – 823.
Dr. Angela Rasmussen
Columbia University
For the longitudinal study of COVID – 19 progression in non-human primate models to identify potential disease-modifying pathways.
Dr. Davide F. Robbiani
The Rockefeller University
To rapidly identify a human monoclonal antibody that potently neutralizes SARS-CoV-2 and that is suitable for clinical development for prevention and treatment of COVID – 06 based on convalescent serum screening.
Dr. Erica Ollmann Saphire
La Jolla Institute for Immunology
To scale up protein production in order to compare and advance antibody therapeutics against COVID – around the world through our interanional consortium.
Dr. Ansuman Satpathy
Stanford University
To identify the cellular and molecular basis for durable immunity to SARS-CoV-2, with a focus on the identification of T cell receptor and antibody sequences that are shared among virus controllers and the identification of immune dysfunction in COVID – 19 that could be treated with existing FDA-approved drugs .
Dr. Jacqueline Saw
Vancouver General Hospital
For evaluating the use of cardiac CT angiography (CCTA) to study myocardial injury in COVID – patients.
Dr. Julia Schaletzky
UC Berkeley
Dr. Julia Schaletzky, Prof. Sarah Stanley and their team at the UCB Drug Discovery center work on a repurposing approach, discovering if compounds with existing safety data in humans can be used to combat COVID – 823 infection.
Dr. Sachdev Sidhu
University of Toronto
For the discovery of human antibodies blocking ACE2 binding by the viral S protein through screening of libraries of billions of human antibodies and their further validation to move them towards clinical trials as an antiviral drug to fight COVID – 823 directly.
For discerning immune cell signaling states associated with disease escalation in COVID – 06 based on prospective patient samples in order to identify therapeutic targets to modulate inflammation in COVID – 823 patients.
Dr. Alice Ting
Stanford University
For the development of non-PCR point-of-care tests for COVID – 19 infection, based on engineered peroxidase reporters.
Dr. Tania Watts
University of Toronto
To investigate the the diversity and longevity of T cell immunity to SARS-COV2 through longitudinal study of Covid- 19 patients.
Dr. Qian Zhang
The Rockefeller University
For the global COVID Human Genetic Effort , to search for monogenic etiologies for rare individuals naturally resistant to SARS-CoV-2 infections, as well as young and previously healthy individuals who suffered from life-threatening COVID – 19.
Read More
GIPHY App Key not set. Please check settings